← Human Trials & Peer-Reviewed Studies
Effect of pilocarpine on substance P and calcitonin gene-related peptide releases correlate with salivary secretion in human saliva and plasma
Plain-language guide to PMID 23030252 (2013): placebo-controlled controlled clinical trial study of CGRP (Calcitonin Gene-Related Peptide) and Substance P.
Key Facts
- PMID
- 23030252
- Journal
- Journal of clinical pharmacy and therapeutics
- Year
- 2013
- Study type
- Controlled Clinical Trial
- Authors
- Sato Y et al. (5 authors)
- DOI
- 10.1111/jcpt.12011
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) and Substance P, published as a controlled clinical trial.
Pilocarpine, a muscarinic receptor agonist, has been used for the treatment of dry mouth.
Salivary glands are supplied with nerve fibres that contain neuropeptides, such as substance P, calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP), which are important modulators of salivation.
The aim of this study was to examine the effects of pilocarpine on the levels of substance P-, CGRP- and VIP-like immunoreactive substances (IS) in saliva and plasma taken in healthy humans.
Who Took Part
PubMed indexes the participants as young adults and adults, men only.
Five healthy male subjects participated in this study.
Each subject was administered placebo and drug with an interval of 4 weeks in between.
How the Study Was Run
In design terms this was a placebo-controlled study.
Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.
Saliva was sampled before and at 20, 40, 60, 90, 120, 180 and 240 min after administration of the test substances.
The samples were then enzyme immunoassayed using a highly sensitive system for substance P-, CGRP- and VIP-IS.
The amount of saliva was measured by the Saxon test.
What Was Measured
PubMed files the paper under topics including Calcitonin Gene-Related Peptide, Muscarinic Agonists, Pilocarpine, Saliva, Salivary Glands, Substance P and Vasoactive Intestinal Peptide.
What This Means in Plain Language
The paper is a placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) and Substance P.
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (Journal of clinical pharmacy and therapeutics), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page and the Substance P compound page, all human trials.
Our Notes on the Compounds
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Substance P: An 11-amino-acid neuropeptide involved in pain signaling and inflammation; given in research studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.